A pilot study of the effect of pullulan‐conjugated Der f 2 allergen‐specific immunotherapy on canine atopic dermatitis

Abstract

The results indicate the effectiveness of Der f 2-P recombinant protein in the treatment of dogs with CAD and testing positive to D. farinae.

An open study on the efficacy of a recombinant Der f 2 (Dermatophagoides farinae) immunotherapy in atopic dogs in Hungary and Switzerland

“…This response rate is similar to previous studies on subcutaneous and intralymphatic ASIT using crude Df extracts. A previous study reported an even higher response rate in 84.6% (11 of 13) of treated dogs, but in that study the clinical criteria as well as study length were different from our study, and a direct comparison with our data is therefore difficult . However, similar to that study, in 47% of our cases withdrawal of immunomodulating medications was possible.…”

“…In agreement with a previous study there was no correlation between the sensitization pattern (polysensitized vs . monosensitized) and treatment outcome . Of the five dogs which were positive only to Df and As, two showed an excellent response, one showed a good response, one a fair response and one was classified as a treatment failure.…”

“…Allermmune ® was developed based on studies showing that over 75% of atopic Japanese dogs were sensitized to Der f 2 . Allermmune ® has been shown to be effective and safe for the therapy of Der f 2‐sensitized laboratory dogs, and a study from Japan demonstrated >80% efficacy of Allermmune ® in the treatment of naturally occurring atopic dogs …”

Atopic dermatitis in cats and dogs: a difficult disease for animals and owners

“…Further and comparative studies are also needed to investigate which alternative application route is most suitable in which clinical situation. Using recombinant allergens such as Dermatophagoides farinae allergen (Der f 2) [ 149 , 150 ] may result in more reproducible results and a higher success rate compared to standard AIT and ILIT [ 151 ]. Modified allergen preparations such as allergoids, allergen peptides as well as alteration with adjuvants may decrease the risk of adverse effects and increase efficacy [ 152 ].…”

Formulations for Allergen Immunotherapy in Human and Veterinary Patients: New Candidates on the Horizon

“…Mannan-dextran-maltodextrin covalently attached to OVA and papain were intradermally injected into BALB/c mice, leading to elevated humoral immune responses, and an IgE-to-IgG-shift ( 43 ). Another potentially useful polysaccharide is pullulan, a polysaccharide which, coupled to HDM allergen Der p 2, and administered to dogs, effectively reduced clinical signs of atopic dermatitis ( 44 ). Carbohydrate-modified ultrafine ceramic-core based nanoparticles, so-called aquasomes, are not biodegradable, and have been applied in the mouse model with ovalbumin (OVA) as model allergen preparation for intradermal application ( 45 ).…”